Table 4 Recent studies in salvage autologous stem cell transplantation (sASCT) in relapsed/refractory multiple myeloma
Study | Type of study | N | ORR (%) | mPFS (months) | mOS (months) |
|---|---|---|---|---|---|
Dhakal B et al. 2020 [135] | Retrospective (no tandem) | 975 | - | 12 | NR 1-y OS 94% |
Goldschmidt H et al. 2020 [147] | Phase 3 (ReLApsE) | 139 (sASCT) vs. 138 (Rd c.) | 82/71 | 20.7/18.8 (ITT) | NR/62.7 (ITT) |
Manjappa S et al. 2018 [140] | Retrospective (no tandem) | 63 (30m, 33 no m) | 92 | 13.8/20.3 | - |
Gössi U et al. 2018 [138] | Retrospective | 86 (sASCT vs. CTna) | 70 | 30.2/13 | 129.6/33.5 |
Veltri LW et al. 2017 [145] | Retrospective | 233 (105 DR) | 81 | 17.6 | 48 |
Nieto Y et al. 2017 [134] | Phase 2 | 74/184 (GBMF vs. MF) | -/70 | 15.1/9.3 | 37.5/23 |
Zannetti BA et al. 2017 [146] | Retrospective | 66 | 94 | 17 | 43 |
Singh Abbi KK et al. 2015 [144] | Retrospective | 75 | 82 | 10.1 | 22.7 |
Cook G et al. 2016 [5] | Phase 3 (Myeloma X) | 89/85 (sASCT vs. CFx12w) | 83/75 | 19/11 | 67/52 |
Sellner L et al. 2013 [142] | Retrospective | 200 | 80.4 | 15.2 | 42.3 |
Michaelis LC et al. 2013 [141] | Retrospective (no tandem) | 187 | 68 | 11.2 | 30 |
Gonsalves WI et al. 2013 [137] | Retrospective | 98 | 86 | 10.3 | 33 |
Auner HW et al. 2013 [133] | Retrospective | 83 | - | 15.5 | 31.5 |
Lemieux E et al. 2013 [139] | Retrospective | 81 | 93 | 18 | 48 |
Shah N et al. 2012 [143] | Retrospective | 44 | 90 | 12.3 | 31.7 |
Gertz MA et al. 2000 [136] | Retrospective | 64 (14 PR, 20 RR, 30 Re) | 34 (CR) | 11.4 | 19.6 |